文献速递头颈部肿瘤放疗

影像学结外侵犯在预测T1-2 N1鼻咽癌预后及化疗获益中的作用:一项多中心回顾性研究

The role of radiologic extranodal extension in predicting prognosis and chemotherapy benefit for T1-2 N1 nasopharyngeal carcinoma: A multicenter retrospective study.
PubMed 文献 · Radiother Oncol · 2022-12-01

这项多中心回顾性研究纳入2005-2017年三个中心治疗的1082例T1-2 N1鼻咽癌患者,评估明确影像学结外侵犯(rENE)的预后价值及化疗疗效。rENE阳性患者无远处转移生存(DMFS)和总生存(OS)更差,多因素分析证实G1-rENE和G2-rENE对远处转移和死亡的预后价值。放化疗与单纯放疗在rENE阳性和阴性组中DMFS和OS均无显著差异,但rENE阳性患者累积顺铂/奈达铂剂量(CCND)>160 mg/m2时DMFS改善。

要点

  • 明确rENE是T1-2 N1鼻咽癌的预后因素,G1和G2分级均与远处转移和死亡风险相关。
  • 在rENE阳性和阴性组中,放化疗与单纯放疗的DMFS和OS均无显著差异。
  • rENE阳性患者CCND>160 mg/m2时DMFS改善,但OS无改善。

核心结论

  • 明确rENE对T1-2 N1鼻咽癌患者具有预后价值。
  • 在rENE阴性患者中,放疗基础上加化疗未影响DMFS和OS。
  • 在rENE阳性患者中,CCND>160 mg/m2的化疗改善了DMFS。

研究设计与样本

  • 多中心回顾性研究,纳入2005-2017年三个中心治疗的1082例T1-2 N1鼻咽癌患者。
  • rENE记录为G1(融合淋巴结团块 comprising ≥2个不可分离淋巴结)或G2(侵犯超出结周脂肪至明显浸润邻近结构)。
  • 采用多因素分析(MVA)评估rENE的预后价值,并分别在rENE阳性和rENE阴性亚组中评估化疗的价值。

主要发现

  • 中心1、2、3分别有139/515(27.0%)、100/365(27.4%)、43/202(21.3%)cN+患者存在rENE。
  • 与rENE阴性相比,rENE阳性患者DMFS和OS更差(均p<0.001)。
  • MVA证实G1-rENE和G2-rENE对远处转移的预后价值(G1:HR 2.933,G2:HR 6.942,均p<0.001)及对死亡的预后价值(G1:HR 1.587,p=0.040;G2:HR 6.162,p<0.001)。
  • 在rENE阳性和阴性组中,放化疗与单纯放疗的DMFS和OS均无显著差异(均p>0.1)。
  • rENE阳性患者CCND>160 mg/m2时DMFS改善(p=0.033),但OS无改善(p=0.197)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: This multicenter retrospective study aimed to investigated the prognostic value of unequivocal radiologic extranodal extension (rENE) and the efficacy of chemotherapy for stage T1-2 N1 nasopharyngeal carcinoma (NPC) in the IMRT era. MATERIALS AND METHODS: We included 1,082 patients treated in 2005-2017 from three centers. rENE was recorded as G1 (coalescent nodal mass comprising ≥ 2 inseparable nodes) or G2 (invading beyond perinodal fat to frankly infiltrate adjacent structures). Multivariable analysis (MVA) evaluated the prognostic value of rENE. The value of chemotherapy was assessed in rENE-positive (rENE + ) and rENE-negative (rENE - ) subset separately. RESULTS: Centers 1, 2, and 3 had 139/515 (27.0 %), 100/365 (27.4 %), and 43/202 (21.3 %) cN + patients with rENE, respectively. Compared to rENE-, rENE + patients had a worse distant metastasis-free survival (DMFS) and overall survival (OS) (all p < 0.001). MVA confirmed the prognostic of both G1-rENE and G2-rENE for distant metastasis [G1: hazard ratio (HR): 2.933, G2: HR: 6.942, all p < 0.001] and death (G1: HR: 1.587, p = 0.040; G2: HR: 6.162, p < 0.001). There was no significant difference for DMFS and OS between chemo-radiotherapy and radiotherapy alone in rENE + and rENE - groups (all p > 0.1). However, rENE + patients with a cumulative cisplatin/nedaplatin dose (CCND) of > 160 mg/m2 had an improved DMFS (p = 0.033) but no OS (p = 0.197). CONCLUSION: Unequivocal rENE is prognostic in patients with T1-2 N1 NPC. Addition of chemotherapy to radiotherapy did not affect DMFS and OS in rENE - patients. Chemotherapy with a CCND of > 160 mg/m2 improved DMFS in rENE + patients.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Hu YJ, Lu TZ, Guo QJ, et al. The role of radiologic extranodal extension in predicting prognosis and chemotherapy benefit for T1-2 N1 nasopharyngeal carcinoma: A multicenter retrospective study. Radiother Oncol. 2022. PMID: 36464180. doi:10.1016/j.radonc.2022.11.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。